

Reference:	FOI.21012.26
Subject:	Treatment of Ovarian Cancer
Date of Request:	13 July 2026

Requested:

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
 - Paclitaxel in combination with a platinum-based compound
 - Platinum-based therapy alone (cisplatin or carboplatin)
 - Bevacizumab in combination with paclitaxel and carboplatin
 - Olaparib
 - Olaparib + Bevacizumab
 - Niraparib
 - Rucaparib
 - Mirvetuximab soravtansine
3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients in response to question 2, due to the low number (less than 5) and has therefore, replaced the figures in the table with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB confirms that fifty-two (52) patients have been treated for advanced Ovarian Cancer, during the period 1 April to 30 June 2026.
2. The UHB provides within the table below, the number of Ovarian Cancer patients that were treated with the listed medications, during the period 1 April to 30 June 2026.

Medication	Number
Paclitaxel in combination with a platinum-based compound	14
Platinum-based therapy alone (cisplatin or carboplatin)	12
Bevacizumab in combination with paclitaxel and carboplatin	*
Olaparib	0
Olaparib + Bevacizumab	0

Niraparib	*
Rucaparib	0
Mirvetuximab soravtansine	*

3. The UHB confirms that it is not participating in any clinical trials for the treatment of Ovarian Cancer.